-DOCSTART- -X- O
Cancer -X- _ O
is -X- _ O
a -X- _ O
leading -X- _ O
cause -X- _ O
of -X- _ O
death -X- _ O
worldwide. -X- _ O
Cervical -X- _ B-Patient
cancer -X- _ I-Patient
caused -X- _ O
by -X- _ O
human -X- _ O
papillomavirus -X- _ O
( -X- _ O
HPV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
major -X- _ O
health -X- _ O
problem -X- _ O
in -X- _ O
women. -X- _ O
DNA -X- _ O
vaccines -X- _ O
are -X- _ O
a -X- _ O
perfect -X- _ O
approach -X- _ O
to -X- _ O
immunization -X- _ O
, -X- _ O
but -X- _ O
their -X- _ O
potency -X- _ O
in -X- _ O
clinical -X- _ O
trials -X- _ O
has -X- _ O
been -X- _ O
insufficient -X- _ O
for -X- _ O
generating -X- _ O
effective -X- _ O
immunity -X- _ O
, -X- _ O
which -X- _ O
may -X- _ O
be -X- _ O
related -X- _ O
to -X- _ O
the -X- _ O
degradation -X- _ O
of -X- _ O
the -X- _ O
DNA -X- _ O
via -X- _ O
nucleases -X- _ O
, -X- _ O
poor -X- _ O
delivery -X- _ O
to -X- _ O
antigen-presenting -X- _ O
cells -X- _ O
( -X- _ O
APCs -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
insufficient -X- _ O
uptake -X- _ O
of -X- _ O
DNA -X- _ O
plasmids -X- _ O
by -X- _ O
cells -X- _ O
upon -X- _ O
injection. -X- _ O
Archaeosome -X- _ B-Intervention
is -X- _ O
a -X- _ O
nano-delivery -X- _ O
systems -X- _ O
based -X- _ O
on -X- _ O
liposomes -X- _ O
with -X- _ O
their -X- _ O
immunological -X- _ O
role -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
for -X- _ O
gene -X- _ O
delivery. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
human -X- _ B-Intervention
papillomavirus -X- _ I-Intervention
type -X- _ I-Intervention
16 -X- _ I-Intervention
genes -X- _ I-Intervention
, -X- _ O
containing -X- _ O
truncated -X- _ O
L1 -X- _ O
, -X- _ O
E6 -X- _ O
, -X- _ O
and -X- _ O
E7 -X- _ O
, -X- _ O
were -X- _ O
simultaneously -X- _ O
used -X- _ O
in -X- _ O
combination -X- _ O
therapy -X- _ O
with -X- _ O
archaeosome -X- _ B-Intervention
and -X- _ O
assessed -X- _ O
in -X- _ O
vivo. -X- _ O
Findings -X- _ O
supported -X- _ O
that -X- _ O
archaeosomes -X- _ B-Outcome
promotes -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccines -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
long-term -X- _ I-Outcome
CTL -X- _ I-Outcome
response -X- _ I-Outcome
was -X- _ I-Outcome
generated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
low -X- _ I-Outcome
antigen -X- _ I-Outcome
dose. -X- _ I-Outcome
Combination -X- _ I-Outcome
therapy -X- _ I-Outcome
with -X- _ I-Outcome
archaeosome -X- _ I-Outcome
/ -X- _ I-Outcome
L1 -X- _ I-Outcome
/ -X- _ I-Outcome
E6 -X- _ I-Outcome
/ -X- _ I-Outcome
E7 -X- _ I-Outcome
vaccines -X- _ I-Outcome
exhibited -X- _ I-Outcome
a -X- _ I-Outcome
strong -X- _ I-Outcome
cytolytic -X- _ I-Outcome
activity -X- _ I-Outcome
against -X- _ I-Outcome
tumor -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
induced -X- _ I-Outcome
prophylactic -X- _ I-Outcome
and -X- _ I-Outcome
therapeutic -X- _ I-Outcome
effect -X- _ I-Outcome
against -X- _ I-Outcome
the -X- _ I-Outcome
development -X- _ I-Outcome
of -X- _ I-Outcome
tumor -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
animal -X- _ I-Outcome
model -X- _ I-Outcome
. -X- _ O

